What is Karyopharm Therapeutics Inc.'s earnings per share (EPS)?

Karyopharm Therapeutics Inc. (KPTI) reported diluted earnings per share of -$17.93 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Karyopharm Therapeutics Inc. (KPTI) Financials

KPTI

FY2025 annual

Revenue $146.1M +0.6% YoY

Net Income -$196.0M -156.5% YoY

EPS (Diluted) -$17.93 YoY not available

Free Cash Flow -$75.4M +40.9% YoY

Market Cap $13.7M as of Oct 10, 2026

Price / Sales 0.1x on $146.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KPTI SEC filings page.

Karyopharm Therapeutics Inc. (KPTI) reported $146.1M in revenue for fiscal year 2025, up 0.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KPTI FY2025 2026-10-03

Stable revenue masks expense-led margin improvement, persistent cash losses, and a liability-heavy balance sheet.

Revenue remained about $146M in both FY2023 and FY2025, while operating margin improved from -88.7% to -62.1%; that is expense reduction, not volume-led leverage. But 2025 operating cash flow of -$75.4M matched FCF because capital spending was effectively zero, exposing weak cash conversion despite the narrower operating loss.

Net loss was $196M against an operating loss of $90.7M in FY2025, so below-operating items materially widened the reported result. Interest expense reached $45.8M, making financing costs an important part of the earnings gap.

FY2025 liabilities of $401M exceeded assets of $108M, leaving a balance sheet reliant on obligations rather than asset backing. Short-term cushion narrowed from earlier years to a 1.1x current ratio in FY2025; reported liquidity equaled 10.1 months of latest annual operating outflow.

Financial Health Signals

Financial Health Score 54/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Karyopharm Therapeutics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Karyopharm Therapeutics Inc. held $63.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $75.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Karyopharm Therapeutics Inc. scores 30/100 among other emerging companies.

Dilution

Karyopharm Therapeutics Inc. had 18M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Karyopharm Therapeutics Inc. scores 91/100 among other emerging companies.

R&D Intensity

Karyopharm Therapeutics Inc. spent $125.6M on research and development in fiscal year 2025, which was 53.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Karyopharm Therapeutics Inc. scores 80/100 among other emerging companies.

Revenue Progress

Karyopharm Therapeutics Inc. reported revenue of $146.1M in fiscal year 2025, against $145.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Karyopharm Therapeutics Inc. scores 44/100 among other emerging companies.

Burn Trend

Karyopharm Therapeutics Inc.'s operations used $75.4M of cash in fiscal year 2025, against $127.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Karyopharm Therapeutics Inc. scores 56/100 among other emerging companies.

Balance Sheet

Karyopharm Therapeutics Inc.'s cash, cash equivalents and investments came to $63.7M at the end of fiscal year 2025, against $401.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Karyopharm Therapeutics Inc. scores 23/100 among other emerging companies.

Altman Z-Score Distress

-23.99

Karyopharm Therapeutics Inc. scores -23.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($13.7M) relative to total liabilities ($401.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Karyopharm Therapeutics Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Karyopharm Therapeutics Inc. reported a net loss of $196.0M while operations used $75.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Karyopharm Therapeutics Inc. reported an operating loss of $90.7M against $45.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$33.4M

YoY-11.9%

QoQ-4.7%

5Y CAGR+8.1%

10Y CAGR+88.5%

Karyopharm Therapeutics Inc. generated $33.4M in revenue in Q2 2026. This represents a decrease of 11.9% from the same quarter a year earlier. Against the prior quarter it is down 4.7%.

EBITDA

-$22.5M

YoY+7.3%

QoQ+15.8%

Karyopharm Therapeutics Inc.'s EBITDA was -$22.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is up 15.8%.

Net Income

-$67.0M

YoY-79.9%

QoQ-199.3%

Karyopharm Therapeutics Inc. reported -$67.0M in net income in Q2 2026. This represents a decrease of 79.9% from the same quarter a year earlier. Against the prior quarter it is down 199.3%.

EPS (Diluted)

-$2.32

Karyopharm Therapeutics Inc. earned -$2.32 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$55.0M

YoY+42.0%

QoQ-39.5%

5Y CAGR-17.2%

10Y CAGR+3.8%

Karyopharm Therapeutics Inc. held $55.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

23M

5Y CAGR-21.4%

10Y CAGR-4.5%

Karyopharm Therapeutics Inc. had 23M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

-67.4%

YoY-3.1pp

QoQ+8.9pp

Karyopharm Therapeutics Inc.'s operating margin was -67.4% in Q2 2026, reflecting core business profitability. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$29.0M

YoY-11.7%

QoQ-14.3%

5Y CAGR-3.1%

Karyopharm Therapeutics Inc. invested $29.0M in research and development in Q2 2026. This represents a decrease of 11.7% from the same quarter a year earlier. Against the prior quarter it is down 14.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

KPTI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPTI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$146.6M	$146.1M+0.6%	$145.2M-0.5%	$146.0M-7.0%	$157.1M-25.1%	$209.8M+94.1%	$108.1M+164.3%	$40.9M+34.8%	$30.3M+1790.1%	$1.6M+942.2%	$154K-38.4%	$250K+9.2%	$229K-40.8%	$387K-39.0%	$634K+317.1%	$152K
R&D Expenses	$121.0M	$125.6M-12.3%	$143.2M+3.2%	$138.8M-6.7%	$148.7M-7.6%	$160.8M+6.6%	$150.8M+23.3%	$122.3M-24.2%	$161.4M+50.4%	$107.3M+23.4%	$86.9M-11.1%	$97.7M+62.6%	$60.1M+111.3%	$28.5M	N/A	$8.6M
SG&A Expenses	$102.0M	$105.2M-8.9%	$115.4M-12.5%	$131.9M-9.3%	$145.4M+1.1%	$143.8M+13.8%	$126.4M+19.9%	$105.4M+115.8%	$48.8M+96.4%	$24.9M+3.9%	$23.9M+11.0%	$21.6M+35.3%	$15.9M+171.0%	$5.9M+142.3%	$2.4M+32.0%	$1.8M
Operating Income	-$82.3M	-$90.7M+24.1%	-$119.4M+7.8%	-$129.5M+8.9%	-$142.2M-44.7%	-$98.3M+42.8%	-$171.8M+9.2%	-$189.3M-5.2%	-$179.9M-37.8%	-$130.5M-17.9%	-$110.7M+7.0%	-$119.1M-57.0%	-$75.8M-123.4%	-$34.0M	N/A	-$10.3M
EBITDA	N/A	-$90.4M+24.1%	-$119.1M+7.7%	-$129.0M+8.9%	-$141.6M-45.2%	-$97.5M+43.0%	-$170.9M+9.3%	-$188.3M-5.1%	-$179.1M-38.0%	-$129.8M-18.0%	-$110.0M+7.1%	-$118.4M-56.8%	-$75.5M-123.4%	-$33.8M	N/A	-$10.2M
Interest Expense	$49.3M	$45.8M+22.5%	$37.4M+57.1%	$23.8M-4.7%	$25.0M-4.0%	$26.0M-4.0%	$27.1M+73.5%	$15.6M+527.6%	$2.5M	N/A	N/A	N/A	$1K	N/A	N/A	N/A
Income Tax	-$32K	$43K-24.6%	$57K-82.4%	$323K-12.5%	$369K+37.7%	$268K-13.3%	$309K+672.5%	$40K+53.8%	$26K-58.7%	$63K-54.7%	$139K+100.1%	-$118.1M-55.8%	-$75.8M-123.2%	-$33.9M	N/A	N/A
Net Income	-$224.7M	-$196.0M-156.5%	-$76.4M+46.6%	-$143.1M+13.4%	-$165.3M-33.2%	-$124.1M+36.8%	-$196.3M+1.7%	-$199.6M-11.9%	-$178.4M-38.3%	-$129.0M-17.7%	-$109.6M+7.3%	-$118.2M-56.0%	-$75.8M-123.2%	-$33.9M	N/A	-$10.3M
EPS (Basic)	N/A	-$17.93-90.5%	-$9.41+49.9%	-$18.79-830.2%	-$2.02-22.4%	-$1.65+39.3%	-$2.72	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$17.93	-$14.00+25.5%	-$18.79	-$2.02-22.4%	-$1.65+39.3%	-$2.72	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	10,935	8,455+11.0%	7,616	81,871-99.9%	75M+4.4%	72M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$33.4M-11.9%	$35.1M+16.8%	$34.1M+11.6%	$44.0M+13.6%	$37.9M-11.4%	$30.0M-9.4%	$30.5M-9.5%	$38.8M+7.7%
R&D Expenses	$29.0M-11.7%	$33.8M-2.4%	$27.7M-16.9%	$30.5M-15.5%	$32.8M-14.6%	$34.6M-2.3%	$33.3M-15.4%	$36.1M+1.6%
SG&A Expenses	$25.9M-9.0%	$26.7M-2.4%	$22.8M-16.2%	$26.6M-3.7%	$28.5M-8.3%	$27.4M-7.4%	$27.2M-11.4%	$27.6M-10.3%
Operating Income	-$22.5M+7.6%	-$26.8M+19.5%	-$17.8M+43.0%	-$15.2M+42.1%	-$24.4M+13.3%	-$33.3M+1.5%	-$31.3M+17.3%	-$26.3M+15.9%
EBITDA	-$22.5M+7.3%	-$26.7M+19.4%	-$17.8M+42.9%	-$15.1M+42.4%	-$24.3M+13.3%	-$33.2M+1.5%	-$31.2M+17.3%	-$26.2M+16.0%
Interest Expense	$13.1M+17.1%	$12.6M+14.2%	$12.6M+12.6%	$11.0M-3.3%	$11.2M+25.5%	$11.0M+86.8%	$11.2M+80.5%	$11.4M+87.5%
Income Tax	$0-100.0%	$1K-97.2%	-$67K+38.5%	$34K+21.4%	$40K-40.3%	$36K-49.3%	-$109K-183.8%	$28K+133.3%
Net Income	-$67.0M-79.9%	-$22.4M+4.6%	-$102.2M-232.0%	-$33.1M-3.3%	-$37.3M-256.6%	-$23.5M+37.2%	-$30.8M+26.4%	-$32.1M+7.1%
EPS (Basic)	-$2.32+46.3%	-$1.02+63.2%	-$7.00-87.7%	-$3.82+0.8%	-$4.32-291.2%	-$2.77+42.9%	-$3.73-936.1%	-$3.85-1183.3%
EPS (Diluted)	-$2.32	-$1.24	-$7.00	-$3.82	-$4.32	-$2.77	-$3.60	-$3.85
Diluted Shares (Avg)	28,938	24,715	N/A	8,669	8,620	8,470	N/A	8,336

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

KPTI Balance Sheet

KPTI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$108.4M-34.1%	$164.4M-31.6%	$240.4M-32.9%	$358.2M+17.3%	$305.3M-2.5%	$313.1M+6.1%	$295.0M-13.5%	$341.2M+89.2%	$180.3M-0.1%	$180.4M-16.3%	$215.4M-2.2%	$220.3M+39.3%	$158.2M+11969.1%	$1.3M	N/A
Current Assets	$103.1M-34.1%	$156.5M-33.1%	$233.9M-33.2%	$350.2M+27.1%	$275.6M-0.3%	$276.5M-0.7%	$278.6M-16.7%	$334.6M+125.4%	$148.4M+12.8%	$131.6M-25.9%	$177.6M-14.5%	$207.8M+31.5%	$158.0M+16457.2%	$954K	N/A
Cash & Equivalents	$60.5M-3.1%	$62.5M+19.6%	$52.2M-61.4%	$135.2M-29.0%	$190.5M+121.7%	$85.9M-33.3%	$128.9M+9.2%	$118.0M+71.1%	$69.0M+38.9%	$49.7M-14.9%	$58.4M-61.3%	$150.6M-3.4%	$156.0M+39791.0%	$391K-94.0%	$6.5M
Short-Term Investments	$3.2M-93.1%	$46.2M-66.8%	$139.2M-2.5%	$142.8M+274.2%	$38.2M-76.6%	$163.3M+22.7%	$133.1M-36.7%	$210.2M+171.3%	$77.5M-3.0%	$79.9M-31.9%	$117.3M+112.8%	$55.1M	$0	$0	$0
Inventory	$4.0M-14.8%	$4.7M+55.7%	$3.0M-28.0%	$4.2M+2.9%	$4.1M+55.3%	$2.6M+664.2%	$346K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0-100.0%	$24.2M+1101.1%	$2.0M+0.7%	$2.0M-93.2%	$29.4M-35.3%	$45.4M+34.1%	$33.9M+291.3%	$8.7M	$0	$0	$0
Total Liabilities	$401.3M+14.5%	$350.4M-7.0%	$376.6M+0.5%	$374.8M-2.6%	$385.0M+46.7%	$262.5M+7.1%	$245.2M+55.2%	$158.0M+210.9%	$50.8M+180.2%	$18.1M+6.2%	$17.1M+26.1%	$13.5M+311.4%	$3.3M-88.7%	$29.2M	N/A
Current Liabilities	$92.1M-0.2%	$92.3M+32.8%	$69.5M+5.4%	$65.9M-10.6%	$73.7M+22.4%	$60.2M+29.9%	$46.4M-1.2%	$46.9M-5.2%	$49.5M+200.2%	$16.5M+8.9%	$15.1M+23.0%	$12.3M+273.7%	$3.3M+70.6%	$1.9M	N/A
Non-Current Liabilities	$309.3M+19.8%	$258.2M-16.0%	$307.2M-0.6%	$308.9M-0.8%	$311.3M+53.9%	$202.3M+1.7%	$198.8M+78.9%	$111.1M+8052.5%	$1.4M-18.2%	$1.7M-14.4%	$1.9M+56.7%	$1.2M	$0-100.0%	$27.3M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	$169.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$292.9M-57.5%	-$186.0M-36.6%	-$136.2M-717.8%	-$16.7M+79.1%	-$79.7M-257.6%	$50.5M+1.6%	$49.8M-72.8%	$183.2M+41.5%	$129.5M-20.2%	$162.2M-18.2%	$198.4M-4.1%	$206.8M+33.5%	$154.9M+655.8%	-$27.9M-120.4%	-$12.7M
Retained Earnings	-$1.8B-12.5%	-$1.6B-5.1%	-$1.5B-10.6%	-$1.3B-14.0%	-$1.2B-10.2%	-$1.1B-22.5%	-$873.3M-29.6%	-$673.7M-36.0%	-$495.3M-35.3%	-$366.1M-42.7%	-$256.5M-85.4%	-$138.3M-121.1%	-$62.6M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$111.3M+6.1%	$131.4M+2.9%	$108.4M-34.1%	$96.2M-49.2%	$104.9M-51.0%	$127.7M-37.5%	$164.4M-31.6%	$189.5M-29.8%
Current Assets	$106.4M+8.7%	$126.3M+5.1%	$103.1M-34.1%	$89.7M-51.4%	$97.9M-53.1%	$120.2M-39.4%	$156.5M-33.1%	$184.8M-29.8%
Cash & Equivalents	$55.0M+42.0%	$90.8M+134.3%	$60.5M-3.1%	$37.7M-48.3%	$38.7M-54.3%	$38.8M+26.6%	$62.5M+19.6%	$72.8M+66.8%
Short-Term Investments	$10.1M-21.9%	$0-100.0%	$3.2M-93.1%	$8.2M-86.5%	$13.0M-80.7%	$31.2M-73.6%	$46.2M-66.8%	$60.7M-63.1%
Inventory	$4.0M-20.0%	$3.6M-24.5%	$4.0M-14.8%	$4.0M-15.1%	$5.0M+43.6%	$4.8M+72.2%	$4.7M+55.7%	$4.7M+50.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$441.5M+28.4%	$397.1M+19.0%	$401.3M+14.5%	$365.5M+4.7%	$343.8M-0.7%	$333.6M-10.7%	$350.4M-7.0%	$349.1M-5.7%
Current Liabilities	$134.2M+35.3%	$117.3M+29.8%	$92.1M-0.2%	$87.2M+41.7%	$99.2M+72.2%	$90.4M+38.3%	$92.3M+32.8%	$61.5M-0.9%
Non-Current Liabilities	$307.3M+25.6%	$279.8M+15.0%	$309.3M+19.8%	$278.3M-3.2%	$244.6M-15.2%	$243.2M-21.0%	$258.2M-16.0%	$287.6M-6.7%
Total Equity	-$330.2M-38.2%	-$265.6M-29.0%	-$292.9M-57.5%	-$269.3M-68.7%	-$238.9M-80.8%	-$205.9M-21.9%	-$186.0M-36.6%	-$159.6M-59.0%
Retained Earnings	-$1.8B-13.8%	-$1.8B-12.3%	-$1.8B-12.5%	-$1.7B-8.1%	-$1.6B-8.2%	-$1.6B-4.1%	-$1.6B-5.1%	-$1.5B-6.1%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

KPTI Cash Flow Statement

KPTI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$65.3M	-$75.4M+40.9%	-$127.5M-37.5%	-$92.7M+38.0%	-$149.6M-39.6%	-$107.1M+33.2%	-$160.2M+16.0%	-$190.8M-19.9%	-$159.1M-115.8%	-$73.7M+12.6%	-$84.4M+10.3%	-$94.0M-82.8%	-$51.4M-69.8%	-$30.3M	N/A	-$8.5M
Depreciation & Amortization	N/A	$296K-12.9%	$340K-35.8%	$530K-14.7%	$621K-21.3%	$789K-18.8%	$972K-0.2%	$974K+32.5%	$735K+3.1%	$713K-0.6%	$717K+13.1%	$634K+96.3%	$323K+124.3%	$144K+18.0%	$122K+47.0%	$83K
Stock-Based Compensation	N/A	$14.1M-23.7%	$18.4M-15.1%	$21.7M-38.7%	$35.4M+18.9%	$29.8M+22.0%	$24.4M+59.6%	$15.3M-11.5%	$17.3M-15.3%	$20.4M-8.4%	$22.3M+30.6%	$17.1M+19.8%	$14.2M+276.2%	$3.8M+479.6%	$653K+2620.8%	$24K
Capital Expenditures	N/A	$0-100.0%	$142K	$0-100.0%	$118K-44.3%	$212K+46.2%	$145K-29.6%	$206K-91.3%	$2.4M+3711.3%	$62K-11.4%	$70K-95.1%	$1.4M-50.0%	$2.8M+4871.9%	$57K-52.9%	$121K-67.8%	$376K
Free Cash Flow	N/A	-$75.4M+40.9%	-$127.6M-37.6%	-$92.7M+38.0%	-$149.7M-39.5%	-$107.3M+33.1%	-$160.4M+16.0%	-$191.0M-18.3%	-$161.5M-118.9%	-$73.8M+12.6%	-$84.5M+11.5%	-$95.4M-75.8%	-$54.3M-78.9%	-$30.3M	N/A	-$8.9M
Investing Cash Flow	$3.0M	$43.4M-54.6%	$95.5M+1102.4%	$7.9M+107.6%	-$104.3M-173.5%	$141.8M+364.2%	-$53.7M-168.4%	$78.5M+172.9%	-$107.7M-729.3%	$17.1M-30.4%	$24.6M	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$78.6M	$30.0M-27.8%	$41.6M+3605.2%	$1.1M-99.4%	$193.7M+163.1%	$73.6M-57.2%	$172.1M+38.4%	$124.3M-60.7%	$316.1M+317.3%	$75.7M+48.0%	$51.2M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$24.9M-33.3%	-$22.7M+41.7%	-$11.8M+54.2%	-$5.9M+69.9%	-$18.7M+51.4%	-$39.0M+10.8%	-$25.8M-38.9%	-$19.5M+34.1%
Depreciation & Amortization	-$3K-103.8%	$12K-84.6%	$19K-76.5%	$121K+45.8%	$78K-14.3%	$78K-8.2%	$81K+5.2%	$83K+3.8%
Stock-Based Compensation	$1.9M-49.0%	$3.0M-15.5%	N/A	$2.8M-33.0%	$3.8M-30.1%	$3.6M-28.4%	N/A	$4.2M-17.6%
Capital Expenditures	N/A	N/A	$0-100.0%	$0	$0	$0-100.0%	-$53K	$0
Free Cash Flow	N/A	N/A	-$11.8M+54.3%	-$5.9M+69.9%	-$18.7M+51.4%	-$39.0M+11.2%	-$25.9M-39.2%	-$19.5M+34.1%
Investing Cash Flow	-$10.0M-154.9%	$3.2M-79.1%	$5.0M-66.2%	$4.8M-35.7%	$18.3M-64.3%	$15.3M-30.3%	$14.8M-44.9%	$7.5M+197.3%
Financing Cash Flow	-$898K-352.2%	$49.8M	$29.7M+4266.5%	$0	$356K	$0	$680K+157.6%	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KPTI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPTI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	-62.1%+20.1pp	-82.2%+6.5pp	-88.7%+1.8pp	-90.5%-43.7pp	-46.8%	-159.0%	-462.8%	-593.0%	-8133.2%	-71903.9%	-47630.4%	-33120.5%	-8772.6%	N/A	-6783.5%
Net Margin	-134.2%	-52.6%+45.4pp	-98.0%	-105.2%	-59.1%	-181.6%	-488.1%	-588.1%	-8036.4%	-71153.9%	-47272.4%	-33090.4%	-8771.8%	N/A	-6783.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-388.3%+12.7pp	-401.0%-303.6pp	-97.4%+2.2pp	-99.6%-32.1pp	-67.5%-8.0pp	-59.6%-22.9pp	-36.6%-14.7pp	-21.9%	N/A	N/A
Return on Assets	-180.8%-134.3pp	-46.5%+13.0pp	-59.5%-13.4pp	-46.2%-5.5pp	-40.6%+22.1pp	-62.7%+5.0pp	-67.7%-15.4pp	-52.3%+19.3pp	-71.5%-10.8pp	-60.8%-5.9pp	-54.9%-20.5pp	-34.4%-12.9pp	-21.4%	N/A	N/A
Current Ratio	1.12-0.6x	1.70-1.7x	3.37-1.9x	5.31+1.6x	3.74-0.9x	4.59-1.4x	6.01-1.1x	7.13+4.1x	3.00-5.0x	7.99-3.7x	11.74-5.2x	16.89-31.1x	47.98+47.5x	0.49	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	5.19+0.3x	4.93+4.1x	0.86+0.5x	0.39+0.3x	0.110.0x	0.090.0x	0.070.0x	0.02	N/A	N/A
Asset Turnover	1.35+0.5x	0.88+0.3x	0.61+0.2x	0.44-0.2x	0.69+0.3x	0.35+0.2x	0.140.0x	0.09+0.1x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.00-0.5x	0.48	N/A
FCF Margin	-51.6%+36.3pp	-87.9%-24.4pp	-63.5%+31.8pp	-95.3%-44.1pp	-51.1%	-148.4%	-467.1%	-532.3%	-4596.8%	-54844.8%	-38178.0%	-23703.5%	-7841.6%	N/A	-5871.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-67.4%-3.1pp	-76.3%	-52.4%	-34.6%+33.2pp	-64.3%+1.4pp	-110.8%	-102.4%	-67.8%+19.0pp
Net Margin	-200.5%	-63.9%+14.3pp	-299.9%	-75.2%+7.5pp	-98.2%-153.8pp	-78.2%	-100.8%	-82.7%+13.1pp
Return on Assets	-60.2%-24.7pp	-17.0%+1.3pp	-94.3%-75.5pp	-34.4%-17.5pp	-35.5%-46.6pp	-18.4%-0.1pp	-18.7%-1.3pp	-16.9%-4.2pp
Current Ratio	0.79-0.2x	1.08-0.3x	1.12-0.6x	1.03-2.0x	0.99-2.6x	1.33-1.7x	1.70-1.7x	3.00-1.2x
Asset Turnover	0.30-0.1x	0.270.0x	0.31+0.1x	0.46+0.3x	0.36+0.2x	0.23+0.1x	0.190.0x	0.20+0.1x
FCF Margin	N/A	N/A	-34.7%+50.0pp	-13.3%+36.9pp	-49.3%+40.7pp	-129.9%	-84.7%-29.6pp	-50.2%+31.9pp

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$292.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Karyopharm Therapeutics Inc. KPTI	FY2025	$146.1M	-$196.0M	N/A	$13.7M	54/100
Cue Biopharma, Inc. CUE	FY2025	$27.5M	-$26.6M	-96.9%	$200.9M	63/100
PolyPid Ltd. PYPD	FY2025	N/A	-$34.2M	N/A	$103.0M	—
Applied Therapeutics, Inc. APLT	FY2024	$455K	-$105.6M	N/A	$14.9M	—
MAIA Biotechnology, Inc. MAIA	FY2025	N/A	-$22.4M	N/A	$75.3M	—
CAMP4 Therapeutics Corporation CAMP	FY2025	$3.5M	-$80.4M	N/A	$236.6M	63/100

Where Karyopharm Therapeutics Inc. Ranks

Frequently Asked Questions

What is Karyopharm Therapeutics Inc.'s annual revenue?

Karyopharm Therapeutics Inc. (KPTI) reported $146.1M in total revenue for fiscal year 2025. This represents a 0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Karyopharm Therapeutics Inc.'s revenue growing?

Karyopharm Therapeutics Inc. (KPTI) revenue grew by 0.6% year-over-year, from $145.2M to $146.1M in fiscal year 2025.

Is Karyopharm Therapeutics Inc. profitable?

No, Karyopharm Therapeutics Inc. (KPTI) reported a net income of -$196.0M in fiscal year 2025.

What is Karyopharm Therapeutics Inc.'s EBITDA?

Karyopharm Therapeutics Inc. (KPTI) had EBITDA of -$90.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Karyopharm Therapeutics Inc.'s operating margin?

Karyopharm Therapeutics Inc. (KPTI) had an operating margin of -62.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Karyopharm Therapeutics Inc.'s free cash flow?

Karyopharm Therapeutics Inc. (KPTI) recorded an outflow of $75.4M in free cash flow during fiscal year 2025. This represents a 40.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Karyopharm Therapeutics Inc.'s operating cash flow?

Karyopharm Therapeutics Inc. (KPTI) recorded an outflow of $75.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Karyopharm Therapeutics Inc.'s total assets?

Karyopharm Therapeutics Inc. (KPTI) had $108.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Karyopharm Therapeutics Inc.'s capital expenditures?

Karyopharm Therapeutics Inc. (KPTI) reported no capital expenditure during fiscal year 2025.

How much does Karyopharm Therapeutics Inc. spend on research and development?

Karyopharm Therapeutics Inc. (KPTI) invested $125.6M in research and development during fiscal year 2025.

How many shares does Karyopharm Therapeutics Inc. have outstanding?

Karyopharm Therapeutics Inc. (KPTI) had 18M shares outstanding as of fiscal year 2025.

What is Karyopharm Therapeutics Inc.'s current ratio?

Karyopharm Therapeutics Inc. (KPTI) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

What is Karyopharm Therapeutics Inc.'s return on assets (ROA)?

Karyopharm Therapeutics Inc. (KPTI) had a return on assets of -180.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Karyopharm Therapeutics Inc.'s P/E ratio?

Karyopharm Therapeutics Inc. (KPTI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $13.7M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Karyopharm Therapeutics Inc.'s price-to-sales ratio?

Karyopharm Therapeutics Inc. (KPTI) trades at 0.1x sales, its market capitalization divided by revenue of $146.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $13.7M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Karyopharm Therapeutics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Karyopharm Therapeutics Inc. (KPTI) held $63.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $75.4M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Karyopharm Therapeutics Inc.'s debt-to-equity ratio negative or not reported?

Karyopharm Therapeutics Inc. (KPTI) has negative shareholder equity of -$292.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Karyopharm Therapeutics Inc.'s Altman Z-Score?

Karyopharm Therapeutics Inc. (KPTI) has an Altman Z-Score of -23.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Karyopharm Therapeutics Inc.'s Piotroski F-Score?

Karyopharm Therapeutics Inc. (KPTI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Karyopharm Therapeutics Inc.'s earnings high quality?

Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $196.0M while operations used $75.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Karyopharm Therapeutics Inc. cover its interest payments?

Karyopharm Therapeutics Inc. (KPTI) reported an operating loss of $90.7M against $45.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Karyopharm Therapeutics Inc.?

Karyopharm Therapeutics Inc. (KPTI) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.